Current page location

Stem Cell Research Center

Stem Cell Research Center
The Stem Cell Research Center (SCRC) aims to understand the fate transition phenomena between somatic and stem cells and to develop tissue-specific differentiation technology which can facilitate various researches such as disease modeling and new drug discovery as well as regenerative medicine. Additionally, the SCRC investigates stem cell-based in vitro evaluation system to replace animal models and to change the paradigm of conventional therapeutics development.

In order to meet these objectives, the SCRC is committed to :
  • Understanding biological and molecular mechanism of cell fate transition between somatic and stem cells
  • Providing stem cell based three-dimensional (3D) organoids model
  • Modeling human diseases in vitro for biological and biochemical therapeutic development
  • Developing 3D cell culture based-disease models and alternative methods of animal experiments
researchers and research statement
Name Research Fields
Janghwan Kim
(Associate Director)
  • Disease modeling and development of therapeutics for neural diseases
  • Understanding reprogramming mechanism and developing new regenerative approach
Cho Rok Jung
  • Functional validation of disease related genes and development of therapeutics
  • Development of 3 dimensional cell based disease model
Mi-Young Son
  • Disease modeling based on induced pluripotent stem cell
  • Stem cell-based 3D gastrointestinal organoids as models of human development and disease
Myung Jin Son
  • Metabolic and mitochondrial regulation in cell fate transition
  • Modeling normal- and disease-state livers using organoid system
Hyun-Soo Cho
  • Development of prediction pipeline for hPSC-derived cells
  • Functional analysis of epigenetic modifiers in hPSC-derived cells
Jung Hwa Lim
  • Functional Analysis of disease related genes
  • Development and evaluation of small molecule cancer drug
  • Evaluation of therapeutic gene transfer for genetic disease
Hyun Mi Kang
  • Development of disease model based on 3-dimensional cells
  • Research on generation/differentiation of kidney organoids
Kyung Hee Noh
  • Novel mechanism for ubiquitination enzyme
  • Development of novel oral bioavailability method
Young-Joo Jeon
  • Molecular analysis of disease targets identified using patient iPSCs
  • Proteomic analysis and identification of novel drug targets
research areas
  • Finding out the biological and molecular mechanism of somatic cell/stem cell fate transformation
  • Development of fate control/reprogramming core technology for somatic cell/stem cell
  • Development of human disease modeling original technology based on stem cell
  • Development of technology utilizing stem cell
  • Verification of disease related gene function and development of original technology for treatment (synthetic compound/gene therapy)
  • Development of disease model based on 3-dimensional cell
  • Stem cells, Reprogramming, and Advanced Therapies
    • Discovery of direct reprogramming phenomena using pluripotent factors
    • Development of cell fate control technology through controlling mitochondria function
    • Development of gene therapy based on gene function
  • Disease modeling, Organoids, and Alternative methods of Animal experiments
    • In vitro maturation of human pluripotent stem cell-derived intestinal organoids
    • Development of computational prediction model for differentiation status of hPSC-derived cells
    • Development of disease model based on 3 dimensional biosimilar culturing method and medicine effectiveness evaluation model
    • Finding intestinal gene expression changes using organoids from Parkinson’s disease iPSCs
    • In vitro and in vivo imaging and tracking of intestinal organoids
    • Research on GM1 gangliosidosis disease modeling using patient-oriented induced pluripotent stem cell
  • Research on the targets related to diseases and development of therapeutics
    • Identification of disease related target gene and verification of function
    • Development of anticancer agents targeting new carcinogenic factors